Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977–2005

2020 ◽  
Vol 152 ◽  
pp. 103-110 ◽  
Author(s):  
Ebbe Laugaard Lorenzen ◽  
Jens Christian Rehammar ◽  
Maj-Britt Jensen ◽  
Marianne Ewertz ◽  
Carsten Brink
2019 ◽  
Vol 186 (2-3) ◽  
pp. 381-385
Author(s):  
Pavel Kundrát ◽  
Cristoforo Simonetto ◽  
Markus Eidemüller ◽  
Julia Remmele ◽  
Hannes Rennau ◽  
...  

Abstract Breast cancer radiotherapy may in the long term lead to radiation-induced secondary cancer or heart disease. These health risks hugely vary among patients, partially due to anatomy-driven differences in doses deposited to the heart, ipsilateral lung and contralateral breast. We identify four anatomic features that largely cover these dosimetric variations to enable personalized risk estimates. For three exemplary, very different risk scenarios, the given parameter set reproduces 63–74% of the individual risk variability for left-sided breast cancer patients. These anatomic features will be used in the PASSOS software to support decision processes in breast-cancer therapy.


2020 ◽  
Vol 22 (11) ◽  
Author(s):  
Lisa Kim ◽  
Emefah C. Loccoh ◽  
Reynaldo Sanchez ◽  
Patrick Ruz ◽  
Uzoma Anaba ◽  
...  

2013 ◽  
Vol 368 (11) ◽  
pp. 987-998 ◽  
Author(s):  
Sarah C. Darby ◽  
Marianne Ewertz ◽  
Paul McGale ◽  
Anna M. Bennet ◽  
Ulla Blom-Goldman ◽  
...  

Author(s):  
A-K Wennstig ◽  
C Wadsten ◽  
H Garmo ◽  
F Wärnberg ◽  
L Holmberg ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 558-558 ◽  
Author(s):  
Bostjan Seruga ◽  
Vesna Zadnik ◽  
Cvetka Grasic Kuhar ◽  
Tanja Marinko ◽  
Darko Zorman ◽  
...  

558 Background: Data show that in post-menopausal women with early breast cancer, longer use of aromatase inhibitor (AI) is associated with increased odds of ischemic heart disease. Here we explore the association between adjuvant AI use and cardiac disease in women undergoing cardiac angiography after a diagnosis of early breast cancer. Methods: We linked a database of 7,681 women who underwent cardiac angiography at the University Clinical Center of Ljubljana between December 2004 and November 2010 with the Cancer Registry for Slovenia. Women with early breast cancer that subsequently underwent cardiac angiography were identified. Information on cardiovascular risk factors was retrieved from the patients’ charts and from discharge letters after cardiac angiography. The endpoint of interest was a diagnosis of ischemic heart disease or left ventricular dysfunction (IHD-LVD) without evidence of valvular heart disease at the time of angiography. Conditional, logistic regression was used to test for associations between variables. Results: Among 117 eligible women 75% (n=88) were postmenopausal and 62% (n=73) had hormonal receptor positive (HR+) disease. Of these 42% (n=31) were treated with AI. Overall, 48% (n=56) of women were found to have IHD-LVD. In patients with HR+ breast cancer, use of AIs was significantly associated with IHD-LVD as compared to tamoxifen alone (HR 2.50, 95% CI 1.01-6.29, p=0.046). For each year of AI therapy, there was a trend for higher odds of IHD-LVD (OR: 1.25, 95% CI 0.95-1.67, p=0.116). This effect appeared independent of age, body mass index, baseline hypertension, hypercholesterolemia, diabetes and heart disease or prior anthracyclines exposure. Among all patients, use of anthracyclines and left-sided irradiation was associated with non-significant increases in IHD-LVD (HR 2.37, 95% CI 0.89-6.09, p=0.45 and HR 1.28, 95% CI 0.69-2.40, p=0.44 respectively). Conclusions: Compared to tamoxifen, AIs are associated with a time dependent increase in IHD-LVD. This risk appears independent of other risk factors for heart disease. Anthracycline exposure and left breast or chest wall radiation showed non-significant associations with IHD-LVD in this small cohort.


2013 ◽  
Vol 63 (1) ◽  
pp. 97-103 ◽  
Author(s):  
Eui Kwan Koh ◽  
Jungju Seo ◽  
Tae Seong Baek ◽  
Eun Ji Chung ◽  
Myonggeun Yoon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document